Adaptive Biotechnologies and Roche's Flatiron Health have partnered to integrate the ClonoSeq minimal residual disease (MRD) assay into Flatiron’s OncoEMR platform, facilitating ordering and review of MRD results within community oncology clinics. This integration aims to increase testing efficiency and deliver real-time disease insights. Artificial intelligence also supports biomanufacturing and prior authorization workflows, with institutions like Ochsner Health adopting AI platforms for clinical productivity enhancements.